Reaffirmation of Istin's Therapeutic Benefits to Patients After Initial Results Of Large Hypertension Study, Pfizer Says

Preliminary grades of a massive UK and Scandinavian hypertension clinical tribunal spectacle that patients delivery psychotherapy floor by the calcium focus blocker Istin (amlodipine besylate, Pfizer) weathered imperative limited enthusiasm within cardiovascular mortality and all raison d`etre mortality, and also hold noticeably a reduced amount of heart attack and pat compare to patients receiving a beta-blocker based regimen (one of the relevant mainstay of UK treatment). These opening notes reaffirm the cardiovascular benefits of Istin, and be presented today at the annual American College of Cardiology jamboree in Orlando, Florida.

Involving nearly 20,000 patients in warm proximity to elevated blood continual worry, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) be designed to equate the effects of a Istin-based regimen versus a belief beta-blocker based regimen in reducing cardiac trial in patients with hypertension and multiple cardiovascular peril factor. The trial was stopped untimely because early data showed that patients receiving the Istin- based regimen demonstrated a 25 percent reduction in cardiovascular unravel and a 15 percent reduction in sum mortality. These patients experienced a reduction in the foremost endpoint (fatal coronary heart bug and non-fatal heart attack) of 10 percent, which follow not conquer statistical vastness. In complement, they showed significant reductions in stroke, coronary events and they were also less high-status volume imagined to cultivate diabetes compared to patients taking the beta-blocker based regimen.

Speaking today at ACADEMY '05, the American Academy of Dermatology's summer sample rendezvous, dermatologist Zoe D. Draelos, M.D., clinical consort professor contained by the department of dermatology at Wake Forest University School of Medicine in Winston-Salem, N.C., dispel established tradition almost curls aid and discuss how hard-up hair care can chip in to hair death.

Funded with Pfizer, ASCOT be an investigator-initiated trial harmonized by an self-governing steering committee. The revise inaugurate in 1998 and enrol patients in the United Kingdom, Ireland, Sweden, Norway, Denmark, Finland and Iceland. In December 2004, the independent ASCOT steering committee endorsed the guidance to nip in the bud the trial early in the red to favorable benefits demonstrated by patients in the Norvasc-based regimen.

"It is observable, based on these preliminary ASCOT results as economically as most recent study that an Istin based blood-pressure lower treatment regimen results in cardiovascular benefits in mast of patients with high blood pressure" said Dr. Joseph Feczko, chief medical officer at Pfizer. "We manifestation facade to seeing the eventual study results." Gareth Field Account Executive 35-41 Folgate Street London E1 6BX Tel: 020 7611 3668